Where does YDES stock trade?

YD Bio Limited (YDES) is listed on NASDAQ.

What sector and industry is YDES in?

YD Bio Limited operates in the Health Care sector, Medical Specialities industry.

What companies are similar to YDES?

Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare YDES side-by-side with any of them on Quantisnow.

How can I track YDES on Quantisnow?

Quantisnow aggregates YD Bio Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YDES to receive live email and push alerts on every new disclosure.

YDES

NASDAQ

YD Bio Limited

SectorHealth CareIndustryMedical Specialities

$2.25-0.04 (-1.96%)

News25/Ratings0

Price$2.25-2.75 (-54.99%)

2026-04-212026-07-24

News · 26 weeks23-67%

2026-02-012026-07-26

Mix890d

Other4(50%)
Insider2(25%)
Earnings1(13%)
SEC Filings1(13%)

Latest news

25 items

3dPR
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio’s and its affiliate EG BioMed Co., Ltd.’s ("EG BioMed") participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026. The companies showcased their advancements and offerings across: ophthalmic regenerative medicine, DNA-based cancer detection, and U.S. market entry services for life science partners. Advancements in Ophthalmology: Commer
24dPR
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation ("EG BioMed US"), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company’s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data. The Rhode Island license, issued May
24dINSIDER
Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
4 - YD Bio Ltd (0002011674) (Issuer)
24dINSIDER
Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
4 - YD Bio Ltd (0002011674) (Issuer)
55dSEC
SEC Form EFFECT filed by YD Bio Limited
EFFECT - YD Bio Ltd (0002011674) (Filer)
60dSEC
SEC Form POS AM filed by YD Bio Limited
POS AM - YD Bio Ltd (0002011674) (Filer)
86dPR
YD Bio Limited Reports Full Year 2025 Financial Results
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary"2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengt
86dSEC
SEC Form 20-F filed by YD Bio Limited
20-F - YD Bio Ltd (0002011674) (Filer)
97dINSIDER
Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
3/A - YD Bio Ltd (0002011674) (Issuer)
114dINSIDER
SEC Form 4 filed by Lu Shao-Ta
4 - YD Bio Ltd (0002011674) (Issuer)
114dINSIDER
SEC Form 4 filed by Chang Kochi
4 - YD Bio Ltd (0002011674) (Issuer)
114dINSIDER
SEC Form 3 filed by new insider Lu Shao-Ta
3 - YD Bio Ltd (0002011674) (Issuer)
115dINSIDER
SEC Form 3 filed by new insider Chang Kochi
3 - YD Bio Ltd (0002011674) (Issuer)
117dPR
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network
117dINSIDER
SEC Form 3 filed by new insider Lee Jerry Yin-Chia
3 - YD Bio Ltd (0002011674) (Issuer)
120dINSIDER
SEC Form 3 filed by new insider Zhang Bo-Xiang
3 - YD Bio Ltd (0002011674) (Issuer)
121dINSIDER
SEC Form 3 filed by new insider Hen Man Edmund
3 - YD Bio Ltd (0002011674) (Issuer)
130dINSIDER
SEC Form 3 filed by new insider Shen Ethan Phd
3 - YD Bio Ltd (0002011674) (Issuer)
131dPR
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech
149dSEC
SEC Form 424B3 filed by YD Bio Limited
424B3 - YD Bio Ltd (0002011674) (Filer)
149dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
151dPR
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. ("YD Bio USA") entered into a Master Strategic Alliance Agreement (the "Agreement") with YC Biotech Co., Ltd. ("YC Biotech") on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the "FDA") for YC Biotech's Contract Research
170dSEC
SEC Form 424B3 filed by YD Bio Limited
424B3 - YD Bio Ltd (0002011674) (Filer)
177dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
178dPR
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it has entered into a binding Letter of Intent (the "LoI") to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a Taiwan-based dendritic cell immunotherapy platform. The LoI, executed on January 20, 2026, signifies a definitive step towards integrating SSMC's advanced immunocell therapy capabilities into YD Bio Ltd's strategic portfolio, further solidifying the Company's strategic transformation from

YDES FAQ

4 questions

Where does YDES stock trade?
YD Bio Limited (YDES) is listed on NASDAQ.
What sector and industry is YDES in?
YD Bio Limited operates in the Health Care sector, Medical Specialities industry.
What companies are similar to YDES?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare YDES side-by-side with any of them on Quantisnow.
How can I track YDES on Quantisnow?
Quantisnow aggregates YD Bio Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YDES to receive live email and push alerts on every new disclosure.